Summary & Overview
CPT 95910: Nerve Conduction Studies, Seven or Eight Studies
Headline: Nerve Conduction Studies (Seven–Eight Studies): Clinical Test with Broad Payer Coverage
Lead: CPT 95910 covers nerve conduction studies comprising seven or eight individual nerve tests, a common component of neuromuscular diagnostic workups used to evaluate peripheral nerve function. This procedure informs diagnosis and management of neuropathies and related conditions and is widely recognized by major payers.
Overview: CPT 95910 represents a bundled set of seven or eight nerve conduction studies performed to assess motor and/or sensory nerve function. Nationally, these studies matter because they provide objective physiological data that guide diagnosis, prognostication, and treatment decisions in neuromuscular medicine. The code is applicable across outpatient diagnostic settings and physician offices.
Payer coverage: The code is recognized by major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare, which affects access and billing practices across care settings.
What readers will learn: This publication outlines how CPT 95910 is defined and used in clinical practice; summarizes payer recognition and common billing modifiers and components; places the code in context with related nerve conduction CPT codes that represent fewer or greater numbers of studies; and highlights clinical scenarios where the procedure typically appears. The piece also identifies where input data are missing for specific service line metadata.
Data notes: Data not available in the input for certain service line metadata.
CPT Code Overview
CPT 95910 describes nerve conduction studies consisting of seven or eight studies. These tests evaluate the function of peripheral nerves by measuring electrical conduction velocities and response amplitudes to help characterize neuropathic disorders. The service is categorized under Neurology / Neuromuscular Procedures and is commonly performed in a diagnostic testing facility (POS 11) or an office (POS 11).
Clinical & Coding Specifications
Clinical Context
A patient presents to a neurology diagnostic testing facility or office with complaints of numbness, tingling, weakness, or suspected peripheral nerve injury. The clinician performs nerve conduction studies to evaluate peripheral nerve function and documents seven or eight individual motor and/or sensory studies appropriate to the affected limb(s). The workflow includes pre-procedure history and medication review (including anticoagulant use codes if applicable), technical setup and electrode placement by a technologist (technical component), real-time data acquisition, and interpretation by a physician or qualified provider (professional component). Findings are reviewed with the patient and incorporated into the diagnostic plan for conditions such as neuropathy, suspected entrapment neuropathy, or follow-up of prior nerve injury.
Coding Specifications
-
Modifier
26: Professional Component — appended when the physician or qualified provider reports only the interpretation and report for the nerve conduction studies separate from the facility or technical service. -
Modifier
TC: Technical Component — appended when the facility or testing center reports only the technical performance of the nerve conduction studies (equipment, technologist time) without the physician interpretation. -
Modifier
59: Distinct Procedural Service — appended when the nerve conduction studies are distinct and separate from other procedures performed on the same day (used to indicate a separate session or anatomic site when required by payer policy).
Provider Taxonomies
-
207RN0400X— Neurology -
2084P0800X— Physical Medicine & Rehabilitation
Related Diagnoses
-
I89.0— Lymphedema, not elsewhere classified (when dual diagnosis required without NEMG)Clinical relevance: Lymphedema may prompt evaluation of peripheral limb symptoms where nerve conduction testing helps exclude neuropathic causes of swelling-related paresthesia or to document concurrent nerve dysfunction when electromyography is not performed.
-
Z79.01— Long term (current) use of anticoagulantsClinical relevance: Documentation of long-term anticoagulant use is relevant to procedural risk assessment and planning for nerve conduction studies, particularly when additional invasive testing (e.g., EMG) might be considered.
-
Z79.02— Long term (current) use of other antithrombotics/anticoagulantsClinical relevance: Similar to
Z79.01, this code denotes chronic antithrombotic medication use and is relevant for procedural risk assessment and documentation when scheduling neuromuscular diagnostic procedures.
Related CPT Codes
| CPT Code | Description |
|---|---|
95905 | Nerve conduction studies; one limb, with comparative or consecutive study of homologous nerve, each limb |
95907 | Nerve conduction studies; motor OR sensory, per study |
95908 | Nerve conduction studies; motor AND sensory, per study |
95909 | Nerve conduction studies; five or six studies |
95911 | Nerve conduction studies; nine or ten studies |
95912 | Nerve conduction studies; 11 or 12 studies |
95913 | Nerve conduction studies; 13 or more studies |
-
95905: Alternative format for single-limb studies with comparative or consecutive homologous nerve testing; may be chosen when the service is limited to one limb with comparative testing. -
95907: Reports an individual motor OR sensory study; used in itemized reporting when counting individual studies toward a total. -
95908: Reports an individual motor AND sensory study; used when both motor and sensory components are obtained in a single study. -
95909: Represents five or six studies and is a lower-volume band compared with95910(seven or eight studies); used when fewer studies are clinically indicated. -
95911: Represents nine or ten studies and is used when additional studies beyond95910are required. -
95912: Represents 11 or 12 studies for higher-volume testing needs. -
95913: Represents 13 or more studies for comprehensive multi-nerve testing. -
Common usage notes:
95910(seven or eight studies) is used when the clinical evaluation requires that number of studies; adjacent codes above or below (95909,95911,95912,95913) are used as alternatives if the actual number of studies performed falls into those ranges.95907and95908are per-study codes that may be used when itemizing individual motor or sensory studies, depending on payer guidance.
National Reimbursement Benchmarks
National commercial mean rates (BUCA) average $172.00 versus Medicare at $127.80 for CPT 95910, indicating commercial payers reimburse notably higher on average than Medicare. UnitedHealth Group and Cigna show the highest mean commercial rates, while Medicare remains the lowest among the listed payers.
Rate dispersion (P75 minus P25) varies by payer: UnitedHealth Group has the widest dispersion (240.33 - 136.17 = $104.16), followed by Cigna (237.00 - 137.41 = $99.59) and Blue Cross Blue Shield (198.33 - 117.80 = $80.53). Aetna (185.00 - 120.43 = $64.57) and BUCA (197.82 - 124.67 = $73.16) are tighter, and Medicare shows a moderate spread (179.00 - 86.00 = $93.00). The table and chart below present the full breakdown.
State Benchmarks
State: AK1 / 50
Alaska Benchmarks
Alaska exhibits a notably wide range in reimbursement rates for CPT code 95910, with Blue Cross Blue Shield showing the largest spread between the 25th and 75th percentiles ($145.56). Commercial payers such as Aetna, UnitedHealth Group, and BUCA display relatively narrower spreads, indicating more consistent rates, while Cigna has a moderate spread of $138.00. Medicare's spread is $92.00, reflecting less variability but also the lowest overall rates.
Compared to national averages, Alaska's commercial payers consistently reimburse at much higher levels. For example, Blue Cross Blue Shield and UnitedHealth Group mean rates in Alaska are over $336.00, far exceeding their national means of $166.14 and $203.66, respectively. The table and chart below present the full breakdown of payer-specific rates and percentiles for Alaska.
Key Insights for Alaska
- Blue Cross Blue Shield and UnitedHealth Group have the highest mean rates in Alaska, both above $336.00, while Medicare is the lowest at $123.80.
- All commercial payers in Alaska reimburse significantly above their respective national averages, with mean rates ranging from $225.82 to $337.39.
- The rate spread is widest for Blue Cross Blue Shield ($145.56), indicating substantial variability in reimbursement compared to other payers.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.